^
Association details:
Biomarker:MDM2 amplification
Cancer:Sarcoma
Drug:milademetan (RAIN-32) (MDM2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Milademetan in Advanced/Metastatic Solid Tumors

Excerpt:
...- MDM2 amplification:...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1521O - A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)

Published date:
09/13/2021
Excerpt:
Of the ten evaluable patients, two had partial responses. Response rate and disease control rate were 20% (95% CI 2.5-55.6) and 50% (95% CI 18.7-81.3), respectively....Milademetan showed acceptable safety profile with some clinical activity in patients with intimal sarcoma with MDM2 amplification.